Novo Nordisk A/S (NVO) FCF Payout Ratio: 165.29%
Is Novo Nordisk A/S’s FCF payout ratio high or low?
Novo Nordisk A/S's FCF payout ratio of 165.29% is 126% above its 5-year average of 73.22%, near the high end of its 5-year range (39.45%–178.56%).
36.64% above its 12-month average of 120.96%.
NVO FCF Payout Ratio Chart
NVO Average FCF Payout Ratio Chart
NVO Current vs Average FCF Payout Ratio Chart
NVO FCF Payout Ratio Metrics
FCF PAYOUT RATIO
165.29%
FCF PAYOUT RATIO AVG TTM
120.96%
FCF PAYOUT RATIO AVG 3Y
81.69%
FCF PAYOUT RATIO AVG 5Y
73.22%
FCF PAYOUT RATIO AVG 10Y
64.63%
FCF PAYOUT RATIO AVG 15Y
48.03%
FCF PAYOUT RATIO AVG 20Y
44.88%
CURRENT VS TTM AVG
+36.64%
CURRENT VS 3Y AVG
+102.34%
CURRENT VS 5Y AVG
+125.75%
CURRENT VS 10Y AVG
+155.73%
CURRENT VS 15Y AVG
+244.13%
CURRENT VS 20Y AVG
+268.30%
Payout Ratio Comparison
FCF Payout Ratio
165.3%
Earnings Payout Ratio
49.8%
Dividend Yield
4.14%
FCF Yield
2.50%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $4.55B | $8.12B | 178.6% |
| 2024 | $9.64B | $6.11B | 63.4% |
| 2023 | $10.36B | $4.70B | 45.4% |
| 2022 | $9.20B | $3.63B | 39.5% |
| 2021 | $7.28B | $3.29B | 45.2% |
| 2020 | $4.89B | $3.30B | 67.4% |
| 2019 | $5.32B | $2.91B | 54.6% |
| 2018 | $4.95B | $2.93B | 59.1% |
| 2017 | $5.23B | $3.03B | 57.9% |
| 2016 | $5.66B | $3.37B | 59.5% |
| 2015 | $4.64B | $1.88B | 40.5% |
| 2014 | $4.44B | $1.93B | 43.4% |
| 2013 | $4.11B | $1.79B | 43.6% |
| 2012 | $3.28B | $1.36B | 41.6% |
| 2011 | $3.14B | $991.23M | 31.6% |
| 2010 | $2.82B | $787.60M | 27.9% |
| 2009 | $2.36B | $0 | 0.0% |
| 2008 | $2.03B | $524.44M | 25.8% |
| 2007 | $1.48B | $434.02M | 29.4% |
| 2006 | $781.35M | $343.28M | 43.9% |
| 2005 | $762.58M | $252.19M | 33.1% |
| 2004 | $816.18M | $272.73M | 33.4% |
| 2003 | $620.01M | $211.00M | 34.0% |
| 2002 | $149.08M | $186.64M | 125.2% |
| 2001 | $60.45M | $146.41M | 242.2% |
| 2000 | $465.59M | $110.92M | 23.8% |
| 1999 | $273.41M | $90.34M | 33.0% |
| 1998 | $214.95M | $68.82M | 32.0% |
| 1997 | $67.82M | $44.92M | 66.2% |
| 1996 | ($20.31M) | $29.98M | N/A (Loss) |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Novo Nordisk A/S FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S FCF Payout Ratio FAQ
- What is the FCF payout ratio for Novo Nordisk A/S (NVO)?
- The FCF payout ratio for NVO stock is 165.29%.
- Is Novo Nordisk A/S's FCF payout ratio high or low?
- Novo Nordisk A/S's FCF payout ratio of 165.29% is 126% above its 5-year average of 73.22%, near the high end of its 5-year range (39.45%–178.56%).
- What is the TTM average FCF payout ratio for Novo Nordisk A/S (NVO)?
- The TTM average FCF payout ratio for NVO stock is 120.96%.
- What is the 3Y average FCF payout ratio for Novo Nordisk A/S (NVO)?
- The 3Y average FCF payout ratio for NVO stock is 81.69%.
- What is the 5Y average FCF payout ratio for Novo Nordisk A/S (NVO)?
- The 5Y average FCF payout ratio for NVO stock is 73.22%.
- What is the 10Y average FCF payout ratio for Novo Nordisk A/S (NVO)?
- The 10Y average FCF payout ratio for NVO stock is 64.63%.
- What is the 15Y average FCF payout ratio for Novo Nordisk A/S (NVO)?
- The 15Y average FCF payout ratio for NVO stock is 48.03%.
- What is the 20Y average FCF payout ratio for Novo Nordisk A/S (NVO)?
- The 20Y average FCF payout ratio for NVO stock is 44.88%.
Novo Nordisk A/S FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2025-12-31 | 178.56% |
| 2024-12-31 | 63.37% |
| 2023-12-31 | 45.37% |
| 2022-12-31 | 39.45% |
| 2021-12-31 | 45.19% |
| 2020-12-31 | 67.36% |
| 2019-12-31 | 54.59% |
| 2018-12-31 | 59.14% |
| 2017-12-31 | 57.95% |
| 2016-12-31 | 59.51% |
| 2015-12-31 | 40.48% |
| 2014-12-31 | 43.37% |
| 2013-12-31 | 43.57% |
| 2012-12-31 | 41.64% |
| 2011-12-31 | 31.59% |
| 2010-12-31 | 27.88% |
| 2008-12-31 | 25.83% |
| 2007-12-31 | 29.39% |
| 2006-12-31 | 43.93% |
| 2005-12-31 | 33.07% |
| 2004-12-31 | 33.41% |
| 2003-12-31 | 34.03% |
| 2002-12-31 | 125.19% |
| 2001-12-31 | 242.22% |
| 2000-12-31 | 23.82% |
| 1999-12-31 | 33.04% |
| 1998-12-31 | 32.02% |
| 1997-12-31 | 66.23% |
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar